Exercise of Options

RNS Number : 5066S

Allergy Therapeutics PLC

24 September 2014

 



24 September 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Exercise of Options

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 188,500 ordinary shares of 0.1p each to be admitted to trading on AIM.  Dealing is expected to commence in these shares on 30 September 2014.  The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company.  The total number of shares in issue (inclusive of the above issue) is 410,055,331 Ordinary shares of 0.1p each.

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	[phone]
James Steel Clare Terlouw
FTI Consulting	[phone]
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the current financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

RDSEAANLAFXLEFF